BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
German mid-sized firms gloomy on outlook, survey finds - 2The most effective method to Guarantee Simple Availability in Seniors' SUVs
- 3Email Promoting Instruments for Compelling Efforts
- 4Shrapnel hits across central Israel, injuring several, causing property damage
- 5Amy Poehler's podcast is a hit. It's also a Trojan horse for talking about women and aging.
- The Incomparable Advanced cameras: Which One Will Win?
- Famous Restroom Beautifying Styles For 2024
- Home Plan Tips for Seniors
- California is completely free of drought for the first time in 25 years
- 5 Fundamental Ways to employ a Criminal Legal counselor
- This Luxurious Thermal Spa In Italy Is Perfect For A Relaxing Escape While Visiting Milan
- France's Senate backs ban on social media platforms for under-15s
- UK to hold fresh pork, other affected Spanish products at border amid African swine fever outbreak
- Two Indonesian UN peacekeepers killed in explosion in Lebanon
